CN116570645B - 一种用于防治血管性痴呆的药物组合物 - Google Patents
一种用于防治血管性痴呆的药物组合物 Download PDFInfo
- Publication number
- CN116570645B CN116570645B CN202310840582.3A CN202310840582A CN116570645B CN 116570645 B CN116570645 B CN 116570645B CN 202310840582 A CN202310840582 A CN 202310840582A CN 116570645 B CN116570645 B CN 116570645B
- Authority
- CN
- China
- Prior art keywords
- parts
- vascular dementia
- total
- preventing
- treating vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000004810 Vascular dementia Diseases 0.000 title claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 19
- ZPIKVDODKLJKIN-NSHDSACASA-N Senkyunolide Chemical compound C1CC=CC2=C1[C@H](CCCC)OC2=O ZPIKVDODKLJKIN-NSHDSACASA-N 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229930182490 saponin Natural products 0.000 claims abstract description 13
- 150000007949 saponins Chemical class 0.000 claims abstract description 13
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 12
- 241000545744 Hirudinea Species 0.000 claims abstract description 10
- 150000001412 amines Chemical class 0.000 claims abstract description 10
- 235000003365 Ilex pubescens Nutrition 0.000 claims abstract description 9
- 241001100932 Ilex pubescens Species 0.000 claims abstract description 9
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 claims abstract description 7
- YMGFTDKNIWPMGF-UCPJVGPRSA-N Salvianolic acid A Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C(=C(O)C(O)=CC=1)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-UCPJVGPRSA-N 0.000 claims abstract description 7
- 229930183842 salvianolic acid Natural products 0.000 claims abstract description 7
- 229930183325 senkyunolide Natural products 0.000 claims abstract description 6
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229930190011 Bufogenin Natural products 0.000 claims abstract description 4
- 239000004380 Cholic acid Substances 0.000 claims abstract description 4
- ATLJNLYIJOCWJE-CWMZOUAVSA-N bufogenin Chemical compound C=1([C@H]2C[C@H]3O[C@@]43[C@H]3[C@@H]([C@]5(CC[C@H](O)C[C@H]5CC3)C)CC[C@@]42C)C=CC(=O)OC=1 ATLJNLYIJOCWJE-CWMZOUAVSA-N 0.000 claims abstract description 4
- 229950006858 bufogenin Drugs 0.000 claims abstract description 4
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims abstract description 4
- 229960002471 cholic acid Drugs 0.000 claims abstract description 4
- 235000019416 cholic acid Nutrition 0.000 claims abstract description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims abstract description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940067137 musk ketone Drugs 0.000 claims abstract description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000005493 rutin Nutrition 0.000 claims abstract description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004555 rutoside Drugs 0.000 claims abstract description 4
- 241000208340 Araliaceae Species 0.000 claims abstract 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract 3
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract 3
- 235000008434 ginseng Nutrition 0.000 claims abstract 3
- 238000002360 preparation method Methods 0.000 claims description 10
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 4
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 4
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 4
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 claims description 3
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 claims description 3
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 claims description 3
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 claims description 2
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 claims description 2
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 2
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 2
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 claims description 2
- 229930194268 Salvianic acid Natural products 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000178 monomer Substances 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 208000012902 Nervous system disease Diseases 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000005013 brain tissue Anatomy 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 235000017709 saponins Nutrition 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 229930182494 ginsenoside Natural products 0.000 description 5
- 229940089161 ginsenoside Drugs 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 210000001168 carotid artery common Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002262 irrigation Effects 0.000 description 2
- 238000003973 irrigation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- VOZHMAYHYHEWBW-NVOOAVKYSA-N Bufotalin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]3(O)C[C@@H]2OC(=O)C)C=CC(=O)OC=1 VOZHMAYHYHEWBW-NVOOAVKYSA-N 0.000 description 1
- VOZHMAYHYHEWBW-UHFFFAOYSA-N Bufotalin Natural products CC(=O)OC1CC2(O)C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 VOZHMAYHYHEWBW-UHFFFAOYSA-N 0.000 description 1
- 206010048964 Carotid artery occlusion Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000212322 Levisticum officinale Species 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical compound C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000001645 levisticum officinale Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000009461 neurocognitive dysfunction Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于神经系统疾病治疗领域，具体涉及一种用于防治血管性痴呆的药物组合物。所述组合物含有丹参总酚酸80‑110份，洋川芎内酯类0.2‑5份，水蛭胺类5‑20份，毛冬青总皂苷30‑50份，蟾毒灵0.05‑0.5份，麝香酮0.01‑0.5份、人参总皂苷10‑20份、胆酸1‑5份、芦丁30‑40份。本发明提供的拆方组合物具有良好的防治血管性痴呆的作用，该组合物可以是由各组分单体混合制备得到，也可以是对中药提取单体组分得到的，各组分在治疗血管性痴呆方面具有较好的协同作用。
Description
技术领域
本发明属于神经系统疾病治疗领域，具体涉及一种用于防治血管性痴呆的药物组合物。
背景技术
血管性痴呆(Vascular Dementia,VD)是由缺血性、出血性及急慢性缺血缺氧性脑血管性疾病引起的脑功能损伤后产生的，以高级神经认知功能障碍为主的临床综合征，发病机制复杂且诱因较多。除常见的卒中，炎症、感染及氧化损伤等亦可增加血管性痴呆的风险。研究表明，炎症反应参与了VD的发生，在脑血管疾病及随后继发的神经损伤中起重要作用，VD 的发病机制复杂且诱因较多，目前临床治疗药物虽能不同程度地改善症状，但并未取得重大突破。
血栓心脉宁是由丹参、川芎、麝香等十味中药加工制成的中成药，具有芳香开窍、益气活血、散瘀止痛的功效，临床上主要用于冠心病、心绞痛等疾病的治疗。其药味多成分复杂，给药物作用物质基础研究带来了诸多不利，且在血管性痴呆方面的药效还有待进一步提高。拆方研究，精确简化组分配伍，对药效作用机理的阐述具有重要的意义，且如何拆方，达到更高的药效，是复杂处方亟待解决的课题。
发明内容
为克服现有技术的不足，本发明提供一种用于防治血管性痴呆的药物组合物。
本发明的目的是通过以下技术方案予以实现的：
一种用于防治血管性痴呆的组合物，所述组合物由如下重量份数的组分组成：丹参总酚酸80-110份，洋川芎内酯类0.2-5份，水蛭胺类5-20份，毛冬青总皂苷30-50份，蟾毒灵0.05-0.5份，麝香酮0.01-0.5份、人参总皂苷10-20份、胆酸1-5份和芦丁30-40份。
优选地，所述丹参总酚酸包括质量比为5-10:20-40:1-5的丹参素、丹酚酸B和迷迭香酸。
优选地，所述洋川芎内酯类选自洋川芎内酯A。
优选地，所述水蛭胺类包括质量比为1-5:1-5的水蛭胺C和水蛭胺A。
优选地，所述毛冬青总皂苷包括质量比为10-15:1的异绿原酸A和毛冬青皂苷B2。
优选地，所述人参总皂苷选自人参皂苷Rb、人参皂苷Rg3、人参皂苷Re中的一种或几种。
优选地，所述人参总皂苷选自人参皂苷Re。
上述组合物的制备方法，包括如下步骤：将丹参总酚酸，洋川芎内酯类，水蛭胺类，毛冬青总皂苷，蟾毒灵，麝香酮、人参皂苷、胆酸和芦丁直接混合或用溶剂分散后即得。
本发明的再一目的是提供上述的组合物在制备防治血管性痴呆方面的产品中的应用。
本发明的有益效果：
（1）本发明提供的拆方组合物具有良好的防治血管性痴呆的作用，该组合物可以是由各组分单体混合制备得到，也可以是对中药提取单体组分得到的，各组分在治疗血管性痴呆方面具有较好的协同作用。
（2）本发明提供的组合物中，异绿原酸A和毛冬青皂苷B2具有较好的协同增效作用，能有效活血开窍、祛风止痛，能有效提高机体血清AchE、5-HT的水平，降低脑组织中TNF-α、IL-1β的水平。
（3）本发明研究特定组成的丹参总酚酸、洋川芎内酯A、水蛭胺类、特定组成的毛冬青总皂苷、蟾毒灵、麝香酮和人参皂苷Re成分，对Ach E、5-HT、TNF-α、IL-1β的影响，清楚而透彻的研究了较好治疗血管性痴呆的活性成分组合物及其机理，弥补了中药组分复杂、药效不明确的缺陷。
具体实施方式
下面结合实施例对本发明技术方案作进一步说明。
实施例1
本实施例用于防治血管性痴呆的药物组合物，按重量份数计，所述组合物由如下组分组成，具体见表1。
制备方法为将上述表格中的各组分按照相应的重量份数混合，即得用于防治血管性痴呆的组合物。
实施例2
本实施例用于防治血管性痴呆的药物组合物，按重量份数计，所述组合物由如下组分组成，具体见表2。
制备方法为将上述表格中的各组分按照相应的重量份数混合，得用于防治血管性痴呆的组合物。
实施例3
本实施例用于防治血管性痴呆的药物组合物，按重量份数计，所述组合物由如下组分组成，具体见表3。
制备方法为将上述表格中的各组分按照相应的重量份数混合，即得用于防治血管性痴呆的组合物。
实施例4
本实施例用于防治血管性痴呆的药物组合物，按重量份数计，所述组合物由如下组分组成，具体见表4。
制备方法为将上述表格中的各组分按照相应的重量份数混合，即得用于防治血管性痴呆的组合物。
对比例1
组合物各单体如下表5。
制备方法为将上述表格中的各组分按照相应的重量份数混合，即得。
对比例2
组合物各单体如下表6。
制备方法为将上述表格中的各组分按照相应的重量份数混合，即得。
对比例3
组合物各单体如下表7。
制备方法为将上述表格中的各组分按照相应的重量份数混合，即得。
试验例1 本发明组合物防治血管性痴呆的药效试验
一、材料和方法
实验材料1.1 实验动物
成年SD大鼠120只，雄性，SPF级，体重220 ± 20 g。购自长春市亿斯实验动物技术有限责任公司，动物生产合格证号：SCXK（吉）-2020-0002。
适应性饲养7天后进入实验期。
1.2 实验药物
受试药物：
血栓心脉宁片，由吉林华康药业股份有限公司提供，批准文号：国药准字Z20030145，批号221003。
对比例1-3、实施例1-4的药物按上述相应的对比例和实施例制备，由吉林华康药业股份有限公司提供。
空白对照：蒸馏水，自制。
1.3 实验试剂
5-HT酶联免疫检测试剂盒、Ach E检测试剂盒、TNF-α检测试剂盒、IL-1β ELISA检测试剂盒均购于上海酶联生物科技有限公司。
2.方法
2.1动物分组
适应性喂养7天后，将120只SPF级成年雄性SD大鼠随机分为12组，每组10只。分别为空白对照组、模型对照组、血栓心脉宁组、对比例1-3组、实施例1高剂量组、实施例1中剂量组、实施例1低剂量组、实施例2-4组。
2.2给药剂量
灌胃给药，1次/d/只，其中，血栓心脉宁组1000mg/kg，实施例1-高剂量组给药80mg/kg，实施例1-中剂量组给药40mg/kg，实施例1-低剂量组给药20mg/kg，其余实施例2-4组和对比例1-3各组给药量与实施例1-中剂量组一致，空白对照组、模型对照组灌胃给予等量蒸馏水。
2.3造模方法
采用“永久性双侧颈总动脉闭塞”来建立血管性痴呆大鼠模型，除空白对照组外，其余各组大鼠使用戊巴比妥钠经腹腔注射麻醉后仰卧位，剃除颈部毛发并进行皮肤消毒。从颈部正中处进行切口，钝性分离双侧颈总动脉(CCA)后用手术缝合线将其永久性结扎。缝合切口后再行局部消毒，小心放回笼内（每笼一只待其完全清醒）。空白对照组大鼠不剥离、不阻断CCA，其余方法相同。手术后的大鼠均放回原笼继续饲养。建模手术结束后第7天，进行灌胃给药，所有实验组连续灌胃28天。
2.4 Morris水迷宫测试
将各组大鼠在正式训练前一天分别放入水中自由游泳2min，使其熟悉水迷宫环境，然后再对各组大鼠正式进行Morris水迷宫测试。定位航行实验历时4天，在实验周期内每日固定时间段训练4次，然后在计算的时候取4次实验的平均值作为大鼠在当日内的潜伏期。训练开始时，将平台置于某一象限，4次训练即将大鼠分别从四个不同的象限放入水中，然后采集这只大鼠在2min内找到并爬上平台所用的时间，即为逃避潜伏期。在站台上稳定10s算找到站台，否则继续记录，如果大鼠在2min内未找到平台，需将其牵引到平台，并停留60s，这时潜伏期记为2min。
2.5大鼠血清Ach E、5-HT活性测定，大鼠脑组织TNF-α、IL-1β含量测定
水迷宫实验后，快速处死大鼠，分别取血清、完整脑组织。大脑组织在冰浴条件下采用机械组织匀浆器制备10%匀浆，按测试指标的要求分装后于-20℃冰箱保存。测定时按照试剂盒说明书要求分别测定血清中Ach E、5-HT以及脑组织中TNF-α、IL-1β 含量。
3.统计学分析
实验数据采用SPSS22.0软件进行统计分析，计量资料以平均值±标准差(Mean ±SD)表示，组间差异采用单因素方差分析，p<0.05为显著性差异。
二、结果
对大鼠上台潜伏期比较的影响结果如下表8所示。
对大鼠血清Ach E、5-HT的影响结果如下表9所示。
对大鼠脑组织TNF-α、IL-1β 的影响结果见表10所示。
结果表明，组合物高、中剂量组，相比于阳性药血栓心脉宁，对血管痴呆性大鼠模型具有明显的提高机体血清Ach E、5-HT的作用，组合物低中高剂量组相比于阳性药血栓心脉宁，能明显降低大鼠水迷宫上台潜伏期，降低大鼠脑组织TNF-α的水平，具有良好的治疗血管性痴呆的作用。
上述详细说明是针对本发明其中之一可行实施例的具体说明，该实施例并非用以限制本发明的专利范围，凡未脱离本发明所为的等效实施或变更，均应包含于本发明技术方案的范围内。
Claims (2)
1.一种用于防治血管性痴呆的药物组合物，其特征在于，所述组合物由如下重量份数的组分组成：丹参总酚酸80-110份，洋川芎内酯类0.2-5份，水蛭胺类5-20份，毛冬青总皂苷30-50份，蟾毒灵0.05-0.5份，麝香酮0.01-0.5份、人参总皂苷10-20份、胆酸1-5份和芦丁30-40份；
所述丹参总酚酸由质量比为5-10:20-40:1-5的丹参素、丹酚酸B和迷迭香酸组成；
所述洋川芎内酯类为洋川芎内酯A；
所述水蛭胺类由质量比为1-5:1-5的水蛭胺C和水蛭胺A组成；
所述毛冬青总皂苷由质量比为10-15:1的异绿原酸A和毛冬青皂苷B2组成；
所述人参总皂苷为人参皂苷Re。
2.一种权利要求1所述的组合物在制备防治血管性痴呆药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310840582.3A CN116570645B (zh) | 2023-07-11 | 2023-07-11 | 一种用于防治血管性痴呆的药物组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310840582.3A CN116570645B (zh) | 2023-07-11 | 2023-07-11 | 一种用于防治血管性痴呆的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116570645A CN116570645A (zh) | 2023-08-11 |
| CN116570645B true CN116570645B (zh) | 2023-09-12 |
Family
ID=87538108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310840582.3A Active CN116570645B (zh) | 2023-07-11 | 2023-07-11 | 一种用于防治血管性痴呆的药物组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116570645B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102507842A (zh) * | 2011-11-13 | 2012-06-20 | 吉林华康药业股份有限公司 | 一种血栓心脉宁片的检测方法 |
| CN103006768A (zh) * | 2012-12-21 | 2013-04-03 | 吉林华康药业股份有限公司 | 血栓心脉宁在制备治疗血管性痴呆的药物中的应用 |
| CN110201118A (zh) * | 2019-06-10 | 2019-09-06 | 吉林修正药业新药开发有限公司 | 一种中药组合物在制备治疗或预防血管性老年痴呆药物中的应用 |
-
2023
- 2023-07-11 CN CN202310840582.3A patent/CN116570645B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102507842A (zh) * | 2011-11-13 | 2012-06-20 | 吉林华康药业股份有限公司 | 一种血栓心脉宁片的检测方法 |
| CN103006768A (zh) * | 2012-12-21 | 2013-04-03 | 吉林华康药业股份有限公司 | 血栓心脉宁在制备治疗血管性痴呆的药物中的应用 |
| CN110201118A (zh) * | 2019-06-10 | 2019-09-06 | 吉林修正药业新药开发有限公司 | 一种中药组合物在制备治疗或预防血管性老年痴呆药物中的应用 |
Non-Patent Citations (1)
| Title |
|---|
| 活血、补肾、化痰三种方法对血管性痴呆大鼠脑组织中超氧化物歧化酶活性和一氧化氮含量的调整;侯仙明;王亚利;牛冰;王鑫国;张凯;王四平;李志庚;;中国临床康复(43);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116570645A (zh) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1843439A (zh) | 消炎止痛外用液及其制备方法 | |
| Wu et al. | Ginsenoside-Rg1 mitigates cardiac arrest-induced cognitive damage by modulating neuroinflammation and hippocampal plasticity | |
| JP2003176234A (ja) | 血液循環を促進する漢方薬組成物及びその製造法 | |
| CN111588792B (zh) | 一种治疗中风后吞咽困难的中成药 | |
| CN116570645B (zh) | 一种用于防治血管性痴呆的药物组合物 | |
| CN111407849A (zh) | 一种治疗慢性硬膜下血肿的中药配方及其制备方法 | |
| CN114869928B (zh) | 用于治疗脑血管疾病的中药组合物及其用途 | |
| CN103768357B (zh) | 一种具有治疗复发性阿弗他溃疡的中药复方组合物 | |
| CN104840581B (zh) | 一种用于治疗母猪产后恶露不尽、发情迟缓的中兽药组合物及其制备方法 | |
| CN109276688B (zh) | 一种用于老年痴呆症的中药组合物 | |
| CN108404044B (zh) | 一种治疗抑郁症的复方植物熏香精油 | |
| CN110841051A (zh) | 一种外用治疗偏头痛的姜白索精油 | |
| CN116999486B (zh) | 一种治疗缺血性中风恢复期的壮药复方药物及其制备方法 | |
| CN114470110B (zh) | 一种有止痛作用的抗鼻炎中药组合物 | |
| CN114306543B (zh) | 一种用于治疗阿尔茨海默病的中药组合物及其制备方法和应用 | |
| CN115624543B (zh) | 治疗偏头痛的药物、药物组合物、其制备方法和制药用途 | |
| CN118286323A (zh) | 归脾汤组合物在预防、治疗或改善认知功能障碍疾病或者调节肠道菌群方面的应用 | |
| CN110522805B (zh) | 用于治疗脱发的中药组合物及其制备方法和应用 | |
| RU2473358C1 (ru) | Композиция, обладающая адаптогенным, гепатопротекторным и иммуномодулирующим действием | |
| CN107998117B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 | |
| CN118178624A (zh) | 一种芍药苷和ChABC的组合在治疗复发抑郁症药物中的用途 | |
| CN100339133C (zh) | 纳米sod与纳米黄芪的组合物 | |
| CN105232902A (zh) | 一种治疗毒蛇咬伤的药物组合物 | |
| CN117379476A (zh) | 一种治疗缺血性中风恢复期的中药组合物及其制备方法 | |
| CN116236543A (zh) | 桑菊清解汤在制备预防或治疗肺纤维化药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |